Clinical Trial Update: Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update (Ndovu RCT) evaluating optimal management of dolutegravir resistance in HIV infection; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Sponsor: University of Nairobi | Conditions: HIV-1-infection | Phase 3 | Status: RECRUITING